Argatroban drug interactions: Difference between revisions
(Created page with "__NOTOC__ {{Argatroban}} {{CMG}}; {{AE}} {{JH}} ==TITLE== <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARGATROBAN INJECTION, SOLUTION [GLAXO...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{JH}} | {{CMG}}; {{AE}} {{JH}} | ||
== | ==Drug Interactions== | ||
====7.1 Heparin==== | |||
If argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparin's effect on the aPTT to decrease prior to initiation of argatroban therapy. | |||
====7.2 Oral Anticoagulant Agents==== | |||
Pharmacokinetic drug-drug interactions between argatroban and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of argatroban and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5) and Clinical Pharmacology (12.2)]. | |||
====7.3 Aspirin/Acetaminophen==== | |||
No drug-drug interactions have been demonstrated between argatroban and concomitantly administered aspirin or acetaminophen [see Clinical Pharmacology (12.3)]. | |||
====7.4 Thrombolytic Agents==== | |||
The safety and effectiveness of argatroban with thrombolytic agents have not been established [see Adverse Reactions (6.3)]. | |||
====7.5 Glycoprotein IIb/IIIa Antagonists==== | |||
The safety and effectiveness of argatroban with glycoprotein IIb/IIIa antagonists have not been established | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARGATROBAN INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c9616c0-a299-4fd5-c8ae-79e6db453595 | publisher = | date = | accessdate = }}</ref> | <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ARGATROBAN INJECTION, SOLUTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9c9616c0-a299-4fd5-c8ae-79e6db453595 | publisher = | date = | accessdate = }}</ref> | ||
Revision as of 19:37, 4 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Drug Interactions
7.1 Heparin
If argatroban is to be initiated after cessation of heparin therapy, allow sufficient time for heparin's effect on the aPTT to decrease prior to initiation of argatroban therapy.
7.2 Oral Anticoagulant Agents
Pharmacokinetic drug-drug interactions between argatroban and warfarin (7.5 mg single oral dose) have not been demonstrated. However, the concomitant use of argatroban and warfarin (5 to 7.5 mg initial oral dose, followed by 2.5 to 6 mg/day orally for 6 to 10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR) [see Dosage and Administration (2.5) and Clinical Pharmacology (12.2)].
7.3 Aspirin/Acetaminophen
No drug-drug interactions have been demonstrated between argatroban and concomitantly administered aspirin or acetaminophen [see Clinical Pharmacology (12.3)].
7.4 Thrombolytic Agents
The safety and effectiveness of argatroban with thrombolytic agents have not been established [see Adverse Reactions (6.3)].
7.5 Glycoprotein IIb/IIIa Antagonists
The safety and effectiveness of argatroban with glycoprotein IIb/IIIa antagonists have not been established
Reference
Adapted from the FDA Package Insert.